
OXiGENE, Inc. company was founded in 1988 and is headquartered in Waltham, Massachusetts. OXiGENE, Inc., a biopharmaceutical company, develops small-molecule therapeutics to treat cancer and eye diseases in the United States. It focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumor progression and visual impairment in ocular diseases. The company's product ZYBRESTAT, which is in Phase II/III pivotal registration study as a potential treatment for anaplastic thyroid cancer, as well as in Phase II clinical trials for other solid tumors, including non-small cell lung cancer and platinum resistant ovarian cancer. It also develops a topical formulation of ZYBRESTAT for ophthalmological diseases and conditions, such as age-related macular degeneration. In addition, OXiGENE develops OXi4503, which is in Phase I clinical trial for solid tumors. It has a strategic collaboration agreement with Symphony Capital Partners, L.P. to support the advancement of ZYBRESTAT for oncology and ophthalmology.

IGENE Biotechnology, Inc. was founded in 1981 and is based in Columbia, Maryland. IGENE Biotechnology, Inc. engages in the development, production, and marketing of specialty biochemical products in the United States and internationally. It focuses on research and development in the areas of fermentation technology, nutrition and health, and marketing of products and applications. The company offers AstaXin, a natural source of astaxanthin, a pigment that imparts the characteristic red color to the flesh of salmon, trout, prawns, and other types of fish and shellfish. It is also venturing to supply astaxanthin as a nutraceutical ingredient. The company sells AstaXin primarily to fish producers in the aquaculture industry principally in the European Union, Japan, Chile, and Canada. IGENE Biotechnology, Inc. has a joint venture agreement with Archer-Daniels-Midland Company to manufacture and sell astaxanthin and derivative products worldwide.

Eczacibasi Pharmaceutical and Industrial Investment (formerly Eczacibasi Pharmaceuticals Manufacturing) helps to keep the residents of Turkey healthy. The company provides a variety of pharmaceutical and health care products, including vitamins, diagnostic substances, and personal care items. Eczacibasi Pharmaceutical has interests in prescription drug marketing and manufacturing firms, as well as health care supply distribution firms. It also sells generic drugs through a partnership with Zentiva (part of Sanofi-Aventis). The firm's real estate division invests in commercial properties. Founded in 1952, Eczacibasi Pharmaceutical is a subsidiary of family owned Turkish industrial group Eczacibasi Holding.

Since its inception in 1740, Whatman knows what it takes to separate the wheat from the chaff. Whatman company makes filters, membranes, and specialty products for applications in the analytical, health care, and bioscience markets in some 70 countries. Whatman company's products can be found in medical devices and diagnostic testing kits. Whatman has also developed technology for the isolation, transportation, storage, and purification of DNA for gathering genetic information. Whatman makes other products such as blotting papers, syringe filters, and chromatography products. Whatman company was acquired by GE Healthcare in 2008.

Amphastar Pharmaceuticals, Inc. is a generic and specialty pharmaceutical company that is engaged in the discovery, development, manufacture and marketing of generic and proprietary pharmaceuticals, innovative delivery systems and active pharmaceutical ingredients. Amphastar’s Management Team takes pride in the Company’s “3H” commitment to "High Quality, High Efficiency and High Technology". In keeping with this pledge of excellence to the consumer, Amphastar will continue to invest in state-of-the-art equipment, research & development, facilities, and the advancement of their employees.

TargeGen is developing small molecule therapeutics to treat cancer and cardiovascular disease. The development-stage firm's lead drug candidate, TG 100-115, could prevent complications after heart attacks. Other therapies in TargeGen's pipeline include a potential treatment for colorectal cancer, non-small cell lung cancer, and macular degeneration, an eye condition that often leads to blindness. The biotech company had been eying an IPO but opted in mid-2005 to stay private and took on an additional round of venture capital financing to fund trials of TG 100-115.

NBTY, Inc. was founded in 1971 and is based in Ronkonkoma, New York. NBTY, Inc. manufactures, markets, and retails nutritional supplements in the United States and worldwide. It offers various products, including vitamins, minerals, and sports and other nutritional supplements; food products, such as fruits, nuts, and confectionery products; and personal care products. The company markets approximately 25,000 products under the brands Nature's Bounty, Ester-C, Solgar, MET-Rx, American Health, Osteo Bi-Flex, Flex-A-Min, SISU, Knox, Sundown, Rexall, Pure Protein, Body Fortress, WORLDWIDE Sport Nutrition, Natural Wealth, Puritan's Pride, Holland & Barrett, GNC (UK), Physiologics, Le Naturiste, De Tuinen, Julian Graves, and Vitamin World. It primarily sells its products to mass merchandisers, club stores, drug store chains and supermarkets, wholesale clubs, independent pharmacies, health food stores, health food store wholesalers, the military and other retailers. The company also sells its products through mail order catalog and the Internet. As of September 30, 2009, it operated 442 Vitamin World stores in the United States; 86 Le Naturiste stores in Canada; 537 Holland and Barrett stores in Europe; 351 Julian Graves stores and 31 GNC (UK) stores in the United Kingdom; 80 De Tuinen stores in the Netherlands; 24 Nature's Way stores in Ireland; and 9 franchise Holland and Barrett stores in South Africa.

USANA Health Sciences was founded in 1992 and is headquartered in Salt Lake City, Utah. USANA Health Sciences, Inc. develops, manufactures, and sells nutritional and personal care products. The company offers two product lines, USANA Nutritionals and Sense. The USANA Nutritionals product line consists of essentials, which include vitamin and mineral supplements that provide a foundation of nutrition for various age groups; optimizers, which are targeted supplements that support cardiovascular health, skeletal/structural health, and digestive health; and macro-optimizers comprising low-glycemic functional foods and other related products. The Sense product line includes personal care products that support healthy skin and hair. Products in this line consist of perfecting essence, gentle daily cleanser, hydrating toner, daytime protective emulsion, eye nourisher, night renewal, serum intensive, rice bran polisher, creme masque, revitalizing shampoo, nourishing conditioner, firming body nourisher, energizing shower gel, and intensive hand therapy. USANA Health Sciences also provides resource materials and sales tools, including product brochures and business forms, as well as sells reprints of other commercial publications. The company distributes its products through network marketing in the United States, Canada, Mexico, Australia, New Zealand, Singapore, Malaysia, Hong Kong, Taiwan, Japan, South Korea, the United Kingdom, and the Netherlands.

Calypte Biomedical Corporation company was founded in 1988 and is headquartered in Portland, Oregon. Calypte Biomedical Corporation engages in the development, manufacture, and distribution of in vitro diagnostic tests primarily for the diagnosis of human immunodeficiency virus (HIV) infection. It focuses on the commercialization of HIV-1/2 rapid tests for the detection of antibodies to HIV-1 and HIV 2 in oral fluid and blood samples using a lateral flow dipstick design. The company also offers HIV-1 BED Incidence EIA Test, which detects HIV-1 infections that have occurred within approximately the prior six months, and could be used by public health agencies to identify those regions and the populations within them where HIV transmission is occurring most recently. Calypte Biomedical, through its 51%-owned joint ventures, Beijing Calypte Biomedical Technology Ltd. and Beijing Marr Bio-Pharmaceutical Co., Ltd., manufactures and markets its products in China.

Nycomed US Inc. (formerly Altana Inc) is a subsidiary of Nycomed, which operates three divisions in the US focused on specialty pharmaceuticals in dermatology. Founded in 1849, Fougera is the largest of the three divisions and is a leading manufacturer and distributor of a wide range of multi-source topical steroids, antibiotics and antifungal products. The PharmaDerm division of Nycomed is dedicated to bringing innovative products to the dermatologists so they can best care for their patients. Nycomed US also markets and sells Savage Laboratories products, which focus on emergency care.
Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.







.webp)
.webp)
.webp)
.webp)
.webp)






